Northern Trust Corp Has $1.03 Million Stake in argenx SE – (ARGX)

Northern Trust Corp increased its holdings in shares of argenx SE – (NASDAQ:ARGX) by 11.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,418 shares of the company’s stock after acquiring an additional 1,285 shares during the quarter. Northern Trust Corp’s holdings in argenx were worth $1,029,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ARGX. Redmile Group LLC raised its position in argenx by 182.2% in the second quarter. Redmile Group LLC now owns 673,300 shares of the company’s stock valued at $55,790,000 after purchasing an additional 434,700 shares during the last quarter. Orbimed Advisors LLC grew its stake in argenx by 19.9% in the second quarter. Orbimed Advisors LLC now owns 599,300 shares of the company’s stock valued at $49,658,000 after acquiring an additional 99,300 shares during the period. BB Biotech AG grew its stake in argenx by 13.2% in the second quarter. BB Biotech AG now owns 449,049 shares of the company’s stock valued at $37,208,000 after acquiring an additional 52,230 shares during the period. Acuta Capital Partners LLC lifted its holdings in shares of argenx by 12.2% in the second quarter. Acuta Capital Partners LLC now owns 453,233 shares of the company’s stock valued at $37,555,000 after purchasing an additional 49,412 shares in the last quarter. Finally, Granahan Investment Management Inc. MA lifted its holdings in shares of argenx by 102.6% in the second quarter. Granahan Investment Management Inc. MA now owns 95,419 shares of the company’s stock valued at $7,906,000 after purchasing an additional 48,319 shares in the last quarter. 64.40% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ARGX stock opened at $105.71 on Thursday. The firm has a market capitalization of $3.40 billion, a price-to-earnings ratio of -75.51 and a beta of 1.67. argenx SE – has a 52-week low of $28.83 and a 52-week high of $111.43.



A number of analysts have issued reports on ARGX shares. Wedbush raised their target price on argenx from $114.00 to $121.00 and gave the stock a “positive” rating in a research report on Tuesday, September 18th. Evercore ISI began coverage on argenx in a research report on Monday, October 15th. They set an “outperform” rating and a $110.00 target price for the company. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $154.00 price target on shares of argenx in a research note on Monday, September 17th. SunTrust Banks boosted their target price on argenx to $132.00 and gave the company an “in-line” rating in a research note on Tuesday, September 18th. Finally, JMP Securities upped their price target on argenx to $150.00 and gave the company an “outperform” rating in a research report on Monday, September 17th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $136.00.

TRADEMARK VIOLATION NOTICE: This report was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://dakotafinancialnews.com/2018/12/06/northern-trust-corp-has-1-03-million-stake-in-argenx-se-argx.html.

argenx Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Read More: Diversification

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply